Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Fmr LLC

Fmr LLC raised its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned approximately 13.29% of Enliven Therapeutics worth $146,157,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Federated Hermes Inc. purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at approximately $2,645,000. Wells Fargo & Company MN increased its holdings in Enliven Therapeutics by 49.9% in the fourth quarter. Wells Fargo & Company MN now owns 16,666 shares of the company’s stock valued at $375,000 after buying an additional 5,548 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Enliven Therapeutics in the fourth quarter worth about $200,000. Geode Capital Management LLC grew its position in shares of Enliven Therapeutics by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 762,718 shares of the company’s stock valued at $17,165,000 after acquiring an additional 12,510 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Enliven Therapeutics by 15.3% in the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company’s stock valued at $1,821,000 after purchasing an additional 10,746 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Up 10.7 %

ELVN opened at $16.51 on Monday. The firm’s fifty day simple moving average is $20.31 and its two-hundred day simple moving average is $23.29. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The company has a market cap of $809.06 million, a price-to-earnings ratio of -8.69 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter. On average, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now directly owns 990,392 shares in the company, valued at $20,629,865.36. This represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the transaction, the chief operating officer now owns 329,977 shares in the company, valued at $7,236,395.61. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,751 shares of company stock valued at $1,178,263 over the last ninety days. Insiders own 29.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.